By Dow Jones Business News, April 22, 2014, 08:53:00 AM EDT <\/p>\n
By Tess Stynes <\/p>\n
Pfizer Inc. ( PFE ) said two Phase 3 studies to evaluate the effectiveness and safety of its treatment for adults with moderate-to-severe plaque psoriasis showed positive results. <\/p>\n
The studies of the twice-daily pill--known as tofacitinib -- at two dosing levels was more effective than a placebo in achieving a response of \"clear\" or \"almost clear\" at 16 weeks and in the portion of patients achieving at least a 75% reduction in the severity and area affected by psoriasis. <\/p>\n
Pfizer plans to submit a supplemental new drug application to the U.S. Food and Drug Administration by early next year. <\/p>\n
Tofacitinib -- sold domestically under the brand name Xeljanz -- is approved in more than 20 countries for adults with hard-to-treat cases of moderate-to-severe rheumatoid arthritis. <\/p>\n
Write to Tess Stynes at tess.stynes@wsj.com<\/a> <\/p>\n Subscribe to WSJ: http:\/\/online.wsj.com?mod=djnwires<\/a> <\/p>\n <\/p>\n See the original post: <\/p>\n Pfizer Treatment for Psoriasis Shows Positive Results in Studies<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" By Dow Jones Business News, April 22, 2014, 08:53:00 AM EDT By Tess Stynes Pfizer Inc. ( PFE ) said two Phase 3 studies to evaluate the effectiveness and safety of its treatment for adults with moderate-to-severe plaque psoriasis showed positive results Continue reading